Abbott Laboratories (ABT)
103.70
+1.19 (1.16%)
NYSE · Last Trade: Oct 25th, 8:07 AM EDT
News & Press Releases
Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?fool.com
Abbott's $7.4B free cash flow and 0.3x debt load contrast sharply with UnitedHealth's $16.1B free cash flow but higher leverage and government policy risk.
Via The Motley Fool · October 24, 2026
MarketBeat Week in Review – 10/19 - 10/23marketbeat.com
A market sell-off spread beyond tech as oil prices surged and AI concerns grew. MarketBeat analysts recap the week's top stories on earnings, from Halliburton to Meta Platforms and General Motors.
Via MarketBeat · October 24, 2026
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomachmarketbeat.com
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.
Via MarketBeat · October 23, 2026
S&P 500 Unusual Volume Movers: Oct. 21, 2026chartmill.com
Via Chartmill · October 21, 2026
Abbott Laboratories (NYSE:ABT) Posts In-Line Q3 Results as Reaffirmed Guidance and Nutrition Separation Pressure Shareschartmill.com
Via Chartmill · October 21, 2026
Abbott Laboratories (NYSE:ABT): A Quality Stock With Durable Fundamentalschartmill.com
Via Chartmill · October 12, 2026
Cologuard Is Working—So Why Isn’t Abbott Stock?marketbeat.com
Abbott's stock fell 4% despite solid Q3 results, as it trimmed full-year sales guidance and announced plans to spin off its Nutrition business into a separate public company by 2027.
Via MarketBeat · October 22, 2026
Abbott: 3 Key Takeaways for Long-Term Investorsfool.com
Pulsed field ablation and expanded cancer screening tools position the core business for accelerated growth beyond historical rates.
Via The Motley Fool · October 21, 2026
Abbott (ABT) Q3 2026 Earnings Call Transcriptfool.com
Abbott plans nutrition spinoff by end of 2027 amid strong Q3 growth.
Via The Motley Fool · October 21, 2026
S&P 500 Top Movers: Oct. 21, 2026 US Sessionchartmill.com
Via Chartmill · October 21, 2026
What Abbott Laboratories (ABT) Said on Its Q3 Earnings Callmarketbeat.com
Abbott Laboratories (NYSE:ABT) reported third-quarter sales growth of 7% and adjusted earnings-per-share growth of 9%, while announcing plans to separate its nutrition business into an independent publicly traded company through a tax-free distribution to shareholders.
Chairman and Chief Executive
Via MarketBeat · October 21, 2026
S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Loserschartmill.com
Via Chartmill · October 21, 2026
Abbott Laboratories’s (NYSE:ABT) Q3 2026 earnings results: revenue in line with expectations
Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 2026, with sales up 14.5% year on year to $...
Via StockStory · October 21, 2026
S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declineschartmill.com
Via Chartmill · October 21, 2026
S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fallchartmill.com
Via Chartmill · October 20, 2026
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy.fool.com
It was Griffin's biggest add for Citadel last quarter.
Via The Motley Fool · October 18, 2026
I Just Invested $4,600 Across 3 Top Dividend Stocks. Here’s What I’m Loading Up on Right Now.fool.com
These companies pay durable and growing dividends.
Via The Motley Fool · October 17, 2026
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cyclefool.com
Rising rates can expose dividend traps, but this Dividend King is built to keep paying.
Via The Motley Fool · October 17, 2026
The Market Is Flashing Warning Signals Not Seen in Years. Here’s Why I Just Bought 3 of SCHD’s Dividend Kings.fool.com
The market's warning signs are driving me to shift my portfolio towards high-quality holdings.
Via The Motley Fool · October 13, 2026
Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sellfool.com
These companies have a long history of dividend growth.
Via The Motley Fool · October 12, 2026
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?fool.com
Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.
Via The Motley Fool · October 12, 2026
AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.fool.com
A super-high yield isn't everything.
Via The Motley Fool · October 11, 2026
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?fool.com
You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.
Via The Motley Fool · October 10, 2026
History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio.fool.com
Abbott has a low-risk profile with significant upside potential.
Via The Motley Fool · October 10, 2026
These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway.fool.com
Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock.
Via The Motley Fool · October 1, 2026